Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03589326 · OUTCOME

Percentage of On-Study Participants With Relapse From CR

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia · Source last updated 2025-11-26

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to approximately 3 to 6 years

What was measured

On-study participants with or without HSCT will be evaluated. Relapse from CR is defined as reappearance of blasts in the blood or BM (\>=5%) or in any extramedullary site after a CR.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2028-07
denom Units Selected
Participants
description
On-study participants with or without HSCT will be evaluated. Relapse from CR is defined as reappearance of blasts in the blood or BM (\>=5%) or in any extramedullary site after a CR.
reporting Status
NOT_POSTED
time Frame
Up to approximately 3 to 6 years
title
Percentage of On-Study Participants With Relapse From CR
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice